KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) FCF Margin (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed FCF Margin for 18 consecutive years, with 331.01% as the latest value for Q1 2026.

  • For Q1 2026, FCF Margin fell 20689.0% year-over-year to 331.01%; the TTM value through Mar 2026 reached 109.85%, down 3864.0%, while the annual FY2025 figure was 33.91%, 3727.0% up from the prior year.
  • FCF Margin hit 331.01% in Q1 2026 for Ionis Pharmaceuticals, down from 78.2% in the prior quarter.
  • Across five years, FCF Margin topped out at 50.01% in Q2 2025 and bottomed at 331.01% in Q1 2026.
  • Average FCF Margin over 5 years is 77.24%, with a median of 77.09% recorded in 2023.
  • Year-over-year, FCF Margin plummeted -46984bps in 2022 and then surged 15219bps in 2023.
  • Ionis Pharmaceuticals' FCF Margin stood at 134.53% in 2022, then soared by 113bps to 17.66% in 2023, then crashed by -343bps to 42.94% in 2024, then plummeted by -82bps to 78.2% in 2025, then tumbled by -323bps to 331.01% in 2026.
  • According to Business Quant data, FCF Margin over the past three periods came in at 331.01%, 78.2%, and 87.23% for Q1 2026, Q4 2025, and Q3 2025 respectively.